Introduction
Microorganisms which enter the body are normally met, recognized and destroyed by cells of the nonspecific immune system: polymorphonuclear granulocytes (PMN), macrophages, natural killer cells and cytotoxic lymphocytes. In the course of this battle against infection, an inflammatory response with the characteristic symptoms of local hyperthermia, swelling, redness and pain may occur. This reaction must be controlled carefully to prevent an overactivation of the immune cells which could result in tissue damage. The defense strategy of this part of the immune system is coordinated and regulated through signaling patterns transmitted in the form of cytokines and lipid mediators.
Granulocyte colony-stimulating factor (G-CSF), which has been cloned and is commercially available in a form approved for clinical use (Filgrastim, Neupogen; Lenograstim, Granocyte), is a pivotal cytokine in this communication network. It targets mainly PMN, stimulating their proliferation, priming them for host defense and intensifying their mature functions. The PMN repertoire of functions employed in host defense include chemotaxis, phagocytosis, intracellular killing and release of metabolic products such as lysosomal enzymes, reactive oxygen species and other signal molecules. Therefore, G-CSF exhibits properties of a hematopoietic growth factor as well as a mediator of anti-infective and inflammatory responses.
G-CSF induces leukocytosis and reduces neutropenia
Injection of G-CSF into rodents increased the production of PMN in the bone marrow and initiated the release of less mature cells into the circulation [1 -4] . In addition, the production of monocytes was stimulated indirectly [5, 6] .
When healthy volunteers were injected with G-CSF subcutaneously (s.c.) their circulating PMN counts declined initially for about 1 h. The activated cells were sequestered in the lung where they adhered to the endothelium of the blood vessels [7 -9] . Subsequently, the PMN count rose above the original level as less mature cells were released from the bone marrow [9] . We recorded a dosedependent increase in the absolute neutrophil count (ANC) in a recent volunteer study. The count remained at a plateau value for the duration of the treatment and returned to pretreatment values within 3 days after the last injection [10] . Furthermore, we observed monocytosis as a result of G-CSF administration [11] . A follow-up study revealed that the increase in monocyte numbers was slower than the increase of the ANC and that the high production rate could not be sustained, despite continued treatment (submitted for publication). An earlier study by another group recorded no change in monocyte counts in response to G-CSF treatment [12] . Furthermore, G-CSF treatment stimulated the production of lymphocytes [7, 13, 14] and increased the numbers of circulating progenitor cells [15] .
Neutrophils are key players in anti-infective defense. Therefore, reversal of neutropenia by application of G-CSF should improve the outcome of infection. In fact, improved neutrophil counts and functions resulting from G-CSF treatment were beneficial in a variety of bacterial infection models with absolute or functional neutropenia. The survival rate of mice made neutropenic with cyclophosphamide and challenged with Pseudomonas aeruginosa, Serratia marcescens or Staphylococcus aureus was improved by treatment with G-CSF [16, 17] .
Similarly, G-CSF was also beneficial to cyclophosphamide-treated mice challenged with the fungal pathogens Candida albicans, Cryptococcus neoformans or Aspergillus fumigatus [16 -19] . Other groups, however, found no beneficial effect in neutropenic murine cryptococcosis [20] and local candidosis [21] . On the other hand, Steinshamn et al. [22] found that G-CSF was beneficial to neutropenic mice with C. albicans infection if used in con-junction with stem cell factor [22] . The many possibilities of using combinations of different endogenous factors are only beginning to be explored.
Newborn rats, known to have impaired PMN functions, challenged with group B streptococci were protected when G-CSF was given prophylactically or simultaneously with challenge in combination with antibiotics [23] or stem cell factor [25] , although pretreatment with G-CSF only had no significant effect on the survival of newborn rats infected with the same pathogen [26] . When G-CSF, which crosses the placenta, was given prenatally 6 days before an LD 90 challenge with group B streptococci at birth, the survival rate of the pups was increased [27] .
In a number of clinical trials, G-CSF was demonstrated to be effective in correcting neutropenia and, therefore, in decreasing the incidence of infections in a variety of neutropenic disorders such as iatrogenic neutropenia (due to chemotherapy, radiotherapy or myelosuppressive drugs), idiopathic neutropenia, leukemic neutropenia, refractory or aplastic anemia and agranulocytosis [28 -35] .
G-CSF augments host defense of non-neutropenic hosts
In addition to recruiting new cells, G-CSF primes neutrophils for enhanced effector functions, thereby further improving host defense. G-CSF improves oxidative burst, phagocytosis, chemotaxis and appears to extend neutrophil lifetime by delaying apoptotic cell death [10, 14, 36] . Thus, increasing numbers of more potent neutrophils are recruited to the focus of infection.
G-CSF has been tested in more than 40 models of nonneutropenic bacterial infection. For example, G-CSF improved survival in a P. aeruginosa burn wound infection model in mice [37 -39] , especially in combination therapy with antibiotics [38] . G-CSF treatment was also beneficial to mice challenged with P. aeruginosa pneumonia after hemorrhage [40] .
In a lethal model of soft tissue infection with P. aeruginosa in mice the survival rate was improved by the administration of G-CSF for 2 days after infection. The mean number of bacteria in the muscle and peripheral blood were significantly lower in the G-CSF-treated mice than in the control group at 24 h after inoculation [41] .
G-CSF was also beneficial in a variety of peritonitis models. Only 2 µg/kg administered to mice and rats, respectively, after the onset of peritonitis brought about by cecal ligation and puncture improved the outcome and synergized with antibiotics [42, 43] , while the administration of a dose of 15 µ/kg G-CSF improved the survival rate as well as the histopathology in the lung and renal and hepatic functions in rats [44] . In a rat cecal puncture model, a correlation was found between the suppression of tumor necrosis factor (TNF) levels and the improved survival effected by G-CSF [45] . G-CSF also furthered the protective actions of antibiotics when a human stool suspension was inoculated into the peritoneum of rats in comparison to controls receiving only antibiotics [46] . Benefits were also obtained in analogous mouse and rat models without concurrent antibiotic therapy (see Fig. 1 Mice pretreated daily with a combination of the antibiotic clarithromycin and G-CSF for 3 days before intravenous challenge with Mycobacterium avium complex and treated further until sacrifice had significantly decreased levels of infection in spleen and lungs compared to those treated with either factor alone or controls [50] .
Mice pretreated for 5 days prior to infection with Listeria monocytogenes survived better than untreated animals and displayed reduced numbers of bacteria in the peritoneal cavity and spleen. This effect was attributed to the accumulation of phagocytic cells at the infection sites and their increased oxidative metabolism [51] . Both SCID, i. e. mice devoid of lymphocytes, and normal mice inoculated intravenously with L. monocytogenes, then injected i. p. with G-CSF for 5 days had lower counts of viable bacteria in their liver than non-treated mice. This augmentation of the anti-listerial activity may be attributed to activated neutrophils, but not γ /δ T cells nor activated macrophages, because the beneficial effects were also observed in the SCID mice [52] .
Although G-CSF primed PMN of chinchillas infected with influenza A virus for oxidative burst and so reversed the virus-induced PMN dysfunction, no decrease in the incidence of pneumococcal disease or mortality was observed when G-CSF was administered i. p. at the time of infection with Streptococcus pneumoniae and for the following 5 days [53] . These results may be explained by the fact that the dose of G-CSF administered in this study was insufficient to stimulate the proliferation of neutrophils in the bone marrow. Fig. 1 Effect of G-CSF on the survival of mice with fecal peritonitis. Percentage survival after 50 h is shown. In a model of sublethal peritonitis anti-G-CSF antiserum was injected prior to 0.3 ml/kg stool suspension. In a model of lethal peritonitis 100 µg/kg G-CSF was injected prior to inoculation with 0.9 ml/kg stool suspension (G-CSF granulocyte colony-stimulating factor)
In most models of pneumonia the effects of G-CSF were also advantageous. G-CSF pretreatment increased neutrophil recruitment into the infected lungs and protected rats against pneumococcal pneumonia [54] , although this effect was not transferable to rats fed a chronic ethanol diet, a model for immunosuppression experienced by alcohol abusers. In a model with Klebsiella pneumoniae, however, G-CSF given for 2 days prior to i. p. ethanol or saline injection and intratracheal bacterial challenge protected both saline and ethanol treated animals by augmenting the recruitment of neutrophils into the lungs and attenuating the adverse effects of ethanol on neutrophil entry into the lung. The G-CSF-treated rats did not become bacteremic and had a much higher survival rate [55] . In rabbits inoculated transtracheally with Pasteurella multocida and administered G-CSF 24 h postchallenge a trend towards improved survival was noted, although the animals showed a slight increase in inflammation of liver, spleen and lung [56] . G-CSF was found to increase the relative risk of death in rats treated before, during and after intrabroncheal application of E. coli with or without hyperoxia [57] . G-CSF administered to mice from 24 h before challenge to 3 days postchallenge improved survival in splenectomized mice exposed to an aerosol of S. pneumoniae [58] .
In summary, G-CSF treatment was found to be beneficial in a broad variety of bacterial infection models. In most cases it was necessary to initiate treatment concurrently with challenge or even as pretreatment, probably because the endogenous production of G-CSF is sufficient once it is initiated. Thus, application of G-CSF will be primarily effective when (a) it is given before endogenous production, (b) endogenous production does not suffice or (c) endogenous production already subsides. Only very few negative side-effects were recorded in these studies, which might be due to the fact that systemic levels of G-CSF are raised in the course of most severe infections. Therefore, the organism is trained to react to G-CSF as an alarm signal. In contrast, other cytokines which are normally only produced locally often have severe side-effects when given systemically. The few situations where G-CSF worsened the course of infection might be explained by the artificial nature of the infection models: the infections were set with a high dosage of bacterial inoculum injected or sprayed directly into the relevant body compartment, a process which is not in concordance with the pathophysiology of normal infections. As a result of G-CSF pretreatment, the bacterial inoculum meets an already multiplied and alert army of leukocytes. Under these circumstances, the fulminant stimulation and the amplified defense may cause damage to the host.
There have been few obervations regarding the effects of G-CSF in the setting of viral infections. G-CSF was found to be effective for the stimulation of nonspecific protection against Sendai virus infection in normal mice [59, 60] . In a mouse model of pneumonitis, G-CSF increased resistance to an intranasal challenge of the Sendai strain of parainfluenzae type I virus when administered prophylactically intranasally, although not when administered simultaneously with challenge, after challenge or via the subcutaneous or intravenous routes [58] .
Trials of G-CSF therapy in non-neutropenic patients with immunodepression and infection have already begun: a randomized placebo-controlled trial of G-CSF in diabetic foot infection produced promising results. The restored neutrophil bactericidal activity measured ex vivo in the blood of G-CSF-treated diabetic patients with infected ulcers corresponded with earlier eradication of pathogens, quicker resolution of cellulitis, shorter hospital stay, shorter duration of antibiotic treatment and less need for surgery in comparison to patients treated with placebo [61] . Similarly, G-CSF was deemed safe and effective in preventing severe neutropenia in patients with advanced HIV infection in a recent trial in which it also reduced the incidence and duration of bacterial infections, incidence of severe bacterial infections, duration of hospital stays for infections and days on which intravenous antibacterial agents were required [62] .
The endogenous role of G-CSF in infection
Low levels of G-CSF appear to be produced constitutively by tissue cells, but the major determinant of tissue and circulating G-CSF levels is exposure to infection or inflammation [63] . Monocytes and macrophages are regarded as the main source of G-CSF. In vitro, they can be stimulated to produce the protein in response to Gram-positive and Gram-negative bacterial elements, e. g., lipopolysaccharide (LPS) [64 -67] , peptidoglycan breakdown products [68] , lipoteichoic acid, heat-killed Staphylococcus aureus [10] and M. avium strains [69] ; pro-inflammatory mediators such as interleukin-1 (IL-1) [66] , tumor necrosis factor-α (TNF-α) [70] and interferon-γ (IFN-γ) [70] or in response to other CSFs, namely granulocyte-macrophage CSF (GM-CSF) [66, 71] , IL-3 [71] and macrophage CSF (M-CSF) [72, 73] .
Apart from monocytes and macrophages, cell populations likely to be close to the site of an inflammation, such as endothelial cells [74, 75] , or which arrive there first, i. e., PMN [76, 77] , are able to release substantial amounts of the factor when activated by the relevant mediators. Furthermore T cells [78] , fibroblasts [79 -84] and other cell populations may respond to some of these signals with the production of G-CSF.
The serum levels of G-CSF measured under different conditions correspond with the observations made above. Under normal circumstances the basal level of G-CSF in the serum is below the limit of detection in rats and humans [84, 85] , although the factor is extractable from the major organs in higher concentrations in both cases. Challenge of rodents with bacterial pathogens induces an increase in serum levels within minutes or hours [84, 86] . This was also observed in a murine fecal peritonitis model (Fig. 1) [47] and in murine endotoxic shock [10] . In each case, the serum levels remained high for a number of hours to days suggesting an important role of G-CSF in host defense.
In infectious disorders, high levels of G-CSF (up to several hundred ng/ml) may be found in patient serum [87, 88] . Patients who are hyperthermic [87, 89] , and especially patients in the acute phase of infection [90] have elevated G-CSF serum levels. These reachd higher peaks in patients during the first course of infection than in those who had recently experienced previous infections [91] . Trauma and sepsis patients also displayed high G-CSF levels which decreased on recovery [92] . In contrast, G-CSF levels are not raised in acute viral infections or in infections with Mycoplasma pneumoniae [88] .
The importance of endogenous G-CSF for the organism was demonstrated in knock-out mice which were chronically neutropenic. Their infection-induced granulopoiesis was severely defective and they were impaired in their ability to control infection with L. monocytogenes [93] . Passive immunization of rats with rabbit anti-G-CSF antibodies resulted in a diminished induction of PMN recruitment and bactericidal activity in response to intrabronchial application of P. aeruginosa [67] , although the circulating PMN counts remained normal. In contrast, we found that the injection of mice with sheep anti-murine G-CSF antiserum for 5 days caused such severe neutropenia that the animals became much more susceptible to infection with a human stool suspension and died from otherwise sublethal fecal peritonitis (see Figure 1) [47]. However, if the anti-G-CSF antiserum was administered concurrently with infection, it did not affect survival or early neutrophilia (3 h) but blunted late neutrophilia (12 h). Therefore, apart from regulating the production of neutrophils in the bone marrow, endogenous G-CSF formation appears to be mandatory for the second line of neutrophil recruitment and, thus, for the resolution of subacute infections.
In states of stress and infection, the rate of neutrophil formation can be increased as much as tenfold, which indicates that the number of available neutrophils plays a major role in the body's own strategy of host defense. After injection of 10 µg/kg G-CSF s. c. into humans, serum G-CSF levels peaked at approximately 100 ng/ml serum and remained above 10 ng/ml for 10 -16 h during which time the production of neutrophils was stimulated. In comparison, G-CSF levels measured in patients with infections were greater than 100 ng/ml serum [94] . The observations that pharmacological doses of G-CSF raise the serum levels of the factor no higher than those attained by endogenous production during infection substantiate the rationale that the potential of G-CSF therapy seems to lie in maintaining the defense signal for a longer time, in initiating the signal earlier or in substituting insufficient endogenous production.
Cairo et al. [95] observed that the production capacity of G-CSF by leukocytes of pre-term neonates was significantly reduced in comparison to full-term newborns and adults. A reduced ability to produce G-CSF has also been shown in HIV patients (D. L. Pitrak, personal communication). For other patient groups with reduced neutrophil response to infection, e. g., diabetics, no studies on G-CSF production capacity are available yet. Such studies are necessary to define clinical situations of G-CSF deficiency, giving a rationale for therapeutic substitution.
G-CSF as an anti-inflammatory cytokine
The promise of improving host defense in infectious disease is overshadowed by the threat of increasing inflammatory reactions, the result of excess immune activation. The inflammatory response is mediated primarily by the monokines TNF-α and IL-1 and the lymphokine IFN-γ. The activity of these cytokines may be reduced not only by down-regulation of their production or secretion, but also by stimulation of the release of their respective antagonists such as IL-1 receptor antagonist (IL-1ra) and soluble TNF receptors (sTNF-R).
In vitro findings
In vitro, G-CSF is a differential promoter of neutrophil function; although oxidative burst is augmented by about 50%, other activities such as phagocytosis and degranulation are hardly affected [14, 36] . Exposure to endotoxin (LPS), the key immunostimulatory component of the Gram-negative bacterial cell wall, is used widely as a model of the unspecific response to bacterial infection. The LPS-induced production of TNF by a variety of rodent macrophage colonies in vitro was not altered in the presence of G-CSF [96] . In contrast, highly purified human monocytes separated from PMN released less TNF in response to LPS when G-CSF was present in the medium (own unpublished results). G-CSF also suppressed TNF secretion by human blood mononuclear cells, i. e., in the absence of neutrophils, in response to allogeneic Daudi cells in vitro [97] . However, the production of cytokines by murine spleen cells in response to bacterial superantigens was not affected by the presence of G-CSF in vitro [98] . These data indicate that the release of TNF by human but not by rodent monocytes/macrophages can be attenuated by G-CSF in vitro.
Effects of G-CSF in rodent leukocytes ex vivo
Exposure of blood from G-CSF-treated donors to inflammogens ex vivo provides a model that includes recruitment of new blood cell subpopulations from bone marrow as well as bystander effects from other cells in the organism, which can contribute to the immunomodulation by G-CSF. When we challenged a variety of different rodent macrophage populations prepared from donor animals, which had been pretreated in vivo with G-CSF, with endotoxin, we found that TNF release was markedly suppressed compared to that of cells from control animals [96] . Another study found that T cells from G-CSF-treated normal mice showed reduced IL-2 and IFN-γ release, while IL-4 production was augmented in response to LPS challenge ex vivo [99] .
In vivo animal experiments
When endotoxic shock was induced in mice and rats by injecting high doses of LPS, the survival rate of animals that had been pretreated with G-CSF was significantly higher than that of controls [96] . A reduced infiltration of leukocytes in LPS-challenged animals might contribute to reduced organ failure [100] . G-CSF further protected against LPS-induced liver injury of galactosamine-sensitized rodents. In both cases the serum levels of TNF were reduced. In addition, G-CSF pretreatment partially attenuated lung injury in LPS-challenged guinea pigs and pigs [101, 102] . G-CSF-treated galactosamine-sensitized mice were also protected from T cell-mediated liver injury initiated by the superantigen staphylococcal enterotoxin B and exhibited reduced IL-2 serum levels without an effect on TNF release [98] . Reduced TNF formation was also noted in some infection models in rats and dogs [45, 46, 49] .
Ex vivo volunteer studies
To investigate whether the anti-inflammatory effect of G-CSF on cytokine release translates to humans, a series of volunteer treatment studies was performed. Ex vivo LPS-stimulated TNF release from monocytes in whole blood of G-CSF-treated volunteers was reduced in comparison to placebo controls (see Figure 2) [11, 103] . These results also held true for a variety of stimuli other than LPS, such as preparations from Gram-positive bacteria, superantigens or phorbol ester.
Ex vivo LPS-inducible IL-1ra release and shedding of sTNF-R was increased in whole blood of these G-CSFtreated volunteers compared to controls, (Figure 2 ) [11] . Concomitantly, their release capacity of the chemoattractive leukotriene B 4 per individual cell was decreased significantly, another anti-inflammatory effect (own unpublished observations). Furthermore, IFN-γ formation by lymphocytes was attenuated in whole blood incubated in the presence of LPS. Thus, the overall anti-inflammatory effect of a single G-CSF injection consisted of attenuated release of pro-inflammatory mediators by monocytes and lymphocytes and in parallel of augmented formation of the respective antagonists by neutrophils.
In a recent study, we examined the effects of daily G-CSF (Filgrastim) treatment for a period of 12 days in 24 healthy volunteers. Compared to a placebo group, TNF-α, IL-12 and IFN-γ release of whole blood samples in response to ex vivo stimulation by LPS was reduced in each Filgrastim group (75, 150 or 300 µg/day) throughout treatment. Thus, the anti-inflammatory effect of G-CSF treatment is also maintained under sustained treatment regimens. The addition of IL-12 to LPS-stimulated blood in vitro lessened the attenuation of IFN-γ and TNF-α -release capacity, indicating that the suppression of IL-12 release is pivotal in the anti-inflammatory activity of G-CSF (submitted for publication).
In vivo experiments in healthy volunteers
The effects of intravenous G-CSF administration 2 h before endotoxin challenge were compared with the effects of s. c. injection 24 h prior to challenge in a recently published cross-over, placebo-controlled trial [104] . G-CSF injection 1 day prior to challenge significantly decreased the levels of IL-8 and attenuated the release of TNF and IL-6. The release of IL-1ra and sTNF-R in response to pretreatment with G-CSF was increased. The challenge with LPS resulted in a further increase in the levels of sTNF-R I and II, while IL-1ra release remained unaltered. Interestingly, administration of G-CSF shortly before LPS boosted the levels of TNF, IL-6, IL-8, IL-1ra and both kinds of sTNF-R. Despite their diverse effects on cytokine release patterns, both treatment regimens resulted in similar positive effects on neutrophil activation and similar changes in surface molecule expression. In addition, both G-CSF pretreatments blocked LPS-induced granulocyte accumulation in the lung. The effects of G-CSF observed were in accordance with animal studies of infection and sepsis described above. However, the inflammatory responses seen in this model may differ significantly from those in septic patients. Furthermore, the biological relevance of these observations must be evaluated in patients with sepsis.
Clinical experiences
The effects of chronic excess of G-CSF were first studied in lethally irradiated mice transplanted with marrow cells expressing G-CSF through a retroviral vector. These animals had high serum G-CSF levels and mostly remained healthy [105] , indicating that G-CSF itself does not initiate an inflammatory response, although neutrophilic granulocytosis and tissue infiltration of lung and liver was observed. This remarkably low toxicity corresponds well with clinical experience: although more than 1.8 million patients have been treated with G-CSF already, reports of side-effects exceeding mild bone pain are very rare. Some pilot data support the notion that this may in part be due to the anti-inflammatory properties of G-CSF: during G-CSF therapy of cancer patients after chemotherapy, serum TNF (three out of five patients) and urinary peptido-leukotriene metabolites decreased [106] . The incidence of septic multiorgan failure, which is currently perceived as a systemic inflammatory reaction, was reduced in 756 pneumonia patients [107] as well as in 37 liver allograft recipients [108] receiving G-CSF therapy. In line with these observations, G-CSF proved to be safe in intensive care and septic patients [109 -111] , who apparently drew benefit from the therapy. In a follow up study, Weiss et. [112] found that G-CSF appeared to counterregulate the hyperactivation of pro-inflammatory processes in patients at risk of sepsis or with sepsis. A safety trial of G-CSF therapy in combination with antibiotics in severe community-acquired pneumonia found no evidence of G-CSF-related lung injury or evidence of extrapulmonary toxicity [113] . In conclusion, G-CSF showed anti-inflammatory activities despite improved host defense not only in preclinical models but also in clinical settings.
Rationale for the use of G-CSF in non-neutropenic infection
The strategy of boosting the immune system with the endogenous mediator G-CSF in non-neutropenic infection promises benefits and threatens drawbacks. The natural response to an infectious disorder already includes the ready and sustained release of G-CSF which affects the whole organism and is interpreted as a stimulatory signal for host defense. The administration of exogenous G-CSF is unlikely to switch on a dormant mechanism but instead enforces the natural defense pathway. However, because the body's reaction to infection with the production of G-CSF is so rapid already, the therapeutic window for enhancing host defense is small. Only absolute or relative lack of endogenous G-CSF production provides indications for G-CSF therapy in these conditions.
Rather, G-CSF therapy may be useful in lengthening the time the defense signal is maintained or in initiating the signal earlier, for instance, when the risk of infection and/or inflammation can be predicted, such as before surgery or in a diabetic patient. The observations discussed above argue that G-CSF does not exacerbate inflammatory processes but instead has anti-inflammatory properties which would be a great advantage for these indications.
In conclusion, the unique pharmacological combination of G-CSF being an anti-infective and anti-inflammatory drug favors clinical trials in non-neutropenic infection, sepsis-prophylaxis as well as chronic inflammatory disorders.
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